NASDAQ:INCY

Incyte Completes Acquisition of Escient Pharmaceuticals

Retrieved on: 
星期四, 五月 30, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Escient, Patient, Inflammation, Covington & Burling, Goldman Sachs, Atopic dermatitis, MRGPRX2, Cholestatic pruritus, CSU, Acquisition, LLP, MRGPRX4, Therapy, Centerview Partners, B cell, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.
  • "We are excited to continue the work started by the Escient team and accelerate the clinical development of these promising therapies."
  • “Over the past six years, Escient has pioneered the characterization of MRGPR biology and advanced two novel candidates, EP262 and E547, into clinical development,” commented Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals.
  • Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction, and Fenwick & West LLP acted as legal counsel for Escient.

Incyte to Present at Upcoming Investor Conference

Retrieved on: 
星期二, 五月 21, 2024
Biotechnology, Pharmaceutical, Health, Oncology, EDT, Conference

Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami.

Key Points: 
  • Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami.
  • The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings

Retrieved on: 
星期二, 五月 21, 2024
Science, Construction & Property, Biotechnology, Research, Pharmaceutical, Oncology, Health, Urban Planning, Patient, DuPont Experimental Station, Growth, King Street, State, Acquisition, Environment, Creativity, Development, City, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced the expansion of its presence in Delaware with the acquisition of two buildings at 1100 North King Street and 1100 North French Street in downtown Wilmington.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced the expansion of its presence in Delaware with the acquisition of two buildings at 1100 North King Street and 1100 North French Street in downtown Wilmington.
  • This acquisition marks Incyte’s fourth expansion in Delaware since establishing operations in Alapocas in 2014.
  • “We are thrilled to reinforce our ongoing commitment to Delaware by expanding our presence here.
  • In addition to enhancing the Wilmington business community, Incyte will provide a wonderful boost to our local economy.

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Retrieved on: 
星期二, 五月 14, 2024
Research, FDA, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Molecule, Relapse, Real, Congress, EHA, ALK2, Disease, Abstract (summary), Translational research, Biology, MPN, Abstract, Activin and inhibin, Haematopoietic system, Polycythemia, Myeloproliferative neoplasm, Cancer, ASCO, Safety, Society, Neoplasm, Impact, Risk, BET, Myelodysplastic syndrome, Combination therapy, Annual general meeting

Incyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA2024) Congress held on June 13-16 in Madrid, Spain, and virtually.

Key Points: 
  • Incyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA2024) Congress held on June 13-16 in Madrid, Spain, and virtually.
  • Key abstracts accepted for presentation at ASCO and EHA include:
    Abstracts will be available to registered attendees on the ASCO Congress platform beginning on May 23, 2024.
  • ET)
    Abstracts are available on the EHA2024 Congress platform and accessible for on-demand viewing until August 15, 2024.
  • Friday, June 14)
    For full session details and data presentation listings, please see the ASCO ( https://conferences.asco.org ) and EHA2024 ( https://ehaweb.org/congress ) online programs.

Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock

Retrieved on: 
星期一, 五月 13, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Security (finance), Share repurchase, Goldman Sachs, Corporation, Growth, Baker, Dutch auction, Cryptocurrency

The Company has commenced a modified “Dutch Auction” tender offer to repurchase shares of its common stock for an aggregate purchase price of up to $1.672 billion (the “tender offer”).

Key Points: 
  • The Company has commenced a modified “Dutch Auction” tender offer to repurchase shares of its common stock for an aggregate purchase price of up to $1.672 billion (the “tender offer”).
  • This would enable the Baker Entities to maintain their current ownership level of approximately 16.4 percent of Incyte’s outstanding common stock.
  • The solicitation and offer to buy common stock will only be made pursuant to the offer to purchase and the other tender offer documents.
  • The Baker Entities, in the aggregate, own 36,833,933 shares of common stock, representing in the aggregate beneficial ownership of approximately 16.4 percent of outstanding common stock as of May 9, 2024.

Incyte to Present at Upcoming Investor Conference

Retrieved on: 
星期四, 五月 2, 2024
Biotechnology, Other Health, Health, General Health, Public Relations, Investor Relations, Pharmaceutical, Oncology, Communications, Other Science, Research, Science, PDT, Bank, Conference

Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas.

Key Points: 
  • Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas.
  • The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

Retrieved on: 
星期二, 四月 23, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Goldman Sachs, American Academy, Hart–Scott–Rodino Antitrust Improvements Act, B cell, LLP, Safety, Skin, Vital signs, Centerview Partners, Research, ECG, Covington & Burling, MRGPRX2, MRGPRX4, Autoimmunity, Therapy, Science, Escient, Incidence, Patient, Acquisition, Multimedia, Atopic dermatitis, CSU

This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

Key Points: 
  • This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • “These drug candidates are the result of the highly innovative research performed by Escient’s employees and scientific collaborators,” said Joshua A. Grass, President and Chief Executive Officer, Escient.
  • Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction and Fenwick & West LLP acted as legal counsel for Escient.
  • The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415.

Incyte to Report First Quarter Financial Results

Retrieved on: 
星期四, 四月 11, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, ID

If you are unable to participate, a replay of the conference call will be available for thirty days.

Key Points: 
  • If you are unable to participate, a replay of the conference call will be available for thirty days.
  • The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415.
  • To access the replay you will need the conference ID number 13745743.
  • The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Retrieved on: 
星期一, 四月 1, 2024
Research, Biotechnology, Other Health, Health, Cosmetics, Pharmaceutical, Retail, Science, Oncology, Dermatology, Vitiligo, Prurigo nodularis, Patient, Collaboration, Asthma, JAK1, HS, Hidradenitis suppurativa, PN, CMS, Autoimmunity, Pharmaceutical industry

Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.

Key Points: 
  • Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.
  • Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
  • CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
  • “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte.